Regeneron was founded in 1988 by Leonard Schleifer, a physician, and George Yancopoulos, a scientist who still leads the company's research efforts. It is headquartered in Tarrytown, New York, on a campus that houses discovery labs, manufacturing, and clinical operations under one roof. That vertical integration is unusual in biotech and gives Regeneron more control over its pipeline than smaller firms typically have.
The company's discovery engine rests on proprietary technologies. The best known is VelocImmune, a line of genetically engineered mice whose immune systems produce antibodies closely resembling human ones. Researchers use these animals to generate drug candidates that can move into development relatively quickly. Regeneron has leaned on this platform to build one of the deeper internal pipelines in the industry.
Human genetics is another pillar. Regeneron acquired the Icelandic genetics company deCODE in 2013 and has since sequenced the DNA of millions of people, looking for naturally occurring variants that point to promising drug targets. In 2025 it expanded this strategy by acquiring the genotyping assets of consumer genetics firm 23andMe out of bankruptcy. The underlying logic is straightforward: targets validated by human biology have a better chance of producing drugs that work.
The Products Behind the Revenue
Regeneron's commercial portfolio spans eye disease, immunology, oncology, and rare conditions. A few products dominate the story.
Eylea. This injection, known generically as aflibercept, treats wet age-related macular degeneration and other retinal diseases that can cause blindness. For roughly a decade it was Regeneron's largest single source of revenue, generating billions of dollars a year in the United States, with Bayer marketing the drug internationally and sharing the economics. The picture has changed: biosimilar copies of aflibercept began reaching the U.S. market in 2024, putting steady price and volume pressure on the franchise. In response, Regeneron launched Eylea HD, a higher-dose formulation approved in 2023 that allows longer intervals between injections and gives patients and physicians an option biosimilars do not yet match.
Dupixent. Developed and commercialized with Sanofi, Dupixent blocks signaling through two immune pathways (IL-4 and IL-13) and has grown into one of the best-selling medicines in the world, with global sales exceeding $10 billion a year in recent periods. It is approved across a widening list of inflammatory conditions: atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, and, as of late 2024, chronic obstructive pulmonary disease with an eosinophilic component—a huge patient population. Regeneron books its share of Dupixent profits rather than its full sales, an arrangement that shapes how its financials look.
The rest of the portfolio. Libtayo, a cancer immunotherapy, returned fully to Regeneron's control in 2022 after a restructuring of the Sanofi partnership. Kevzara for rheumatoid arthritis and Praluent for high cholesterol also came out of that collaboration. On the rare-disease side, Evkeeza treats an inherited condition causing extremely high cholesterol, and Inmazeb was the first approved treatment for Ebola. These products are smaller in dollar terms but add breadth.
There is also a cautionary tale in the lineup. REGEN-COV, Regeneron's antibody therapy for COVID-19, produced enormous revenue in 2021, then effectively vanished as coronavirus variants emerged that the antibodies could not neutralize. Regulators wound down its authorization. The episode demonstrated how quickly a concentrated revenue stream can evaporate, and it partly explains why investors scrutinize the company's dependence on individual products.
Why Dupixent Matters So Much
With Eylea under pressure, Dupixent has become the growth story investors watch most closely. Its expansion into COPD alone could add billions in annual sales over time, since the disease affects hundreds of millions of people worldwide and existing biologics have played a small role in treatment. Each new approved indication deepens the moat: dermatologists, pulmonologists, allergists, and gastroenterologists all now prescribe the same molecule.
The trade-off is structural. Because Sanofi leads commercialization and the two companies split profits, Regeneron's reported Dupixent revenue is a fraction of the drug's global sales. Bulls argue the profit share still translates into a high-margin, durable earnings stream. Bears point out that Regeneron does not fully control the asset's strategy, and that any setback—patent challenges, competing drugs, safety signals—would hit its income statement even if the failure happened outside its hands.
Growth Drivers Beyond Current Blockbusters
The pipeline is where Regeneron tries to answer the question every large biotech eventually faces: what replaces the drugs that mature? Several directions stand out.
Genetic medicines are a major bet. Through a partnership with Alnylam, Regeneron is developing RNA-interference therapies that silence disease-causing genes, and a collaboration with Intellia applies CRISPR gene-editing technology to additional targets. These modalities could produce long-lasting treatments delivered far less frequently than conventional drugs.
In oncology, Regeneron is developing bispecific antibodies—engineered proteins that link immune cells to cancer cells—particularly for blood cancers, alongside expanding use of Libtayo in solid tumors. In immunology and cardiometabolic disease, programs aim at conditions ranging from chronic urticaria to genetic forms of high cholesterol.
None of this guarantees success. Clinical trials fail more often than they succeed, even at experienced companies. But the breadth of the pipeline, funded by a profitable commercial business, is a genuine differentiator compared with biotechs that depend on one or two shots.
The Main Risks to Understand
Anyone evaluating REGN should weigh these issues honestly.
Biosimilar competition is the immediate one. Eylea's erosion is not hypothetical; it is visible in quarterly results, and the pace of decline will shape near-term earnings. Eylea HD's ability to offset that loss is a central open question.
Concentration is the second. Dupixent and Eylea together account for the overwhelming majority of revenue. REGEN-COV's collapse showed what happens when one pillar breaks.
Policy risk is real for any large U.S. drugmaker. Under the Inflation Reduction Act, Medicare now negotiates prices for selected drugs, and Eylea has been selected in that process. How negotiated prices affect retinal-disease treatment economics will take years to fully play out.
Patent timelines matter on a longer horizon. Dupixent's protection runs well into the next decade, but biosimilar planning starts years early, and the market prices these dates in gradually rather than all at once.
Financial Profile and Shareholder Returns
Regeneron has been solidly profitable for years, with total revenues above $13 billion annually in recent periods and margins that reflect its integrated manufacturing model. It carries a substantial cash balance and modest debt, which gives management flexibility to fund the pipeline, make acquisitions, and weather setbacks.
The company pays no dividend. Instead, it has directed capital toward share repurchases and reinvestment in research. Investors seeking income will not find it here; those interested in compounding through a growing (if bumpy) earnings stream have historically had a different calculus. The stock trades as a large-cap growth holding and is a component of the S&P 500.
How to Research REGN Before Investing
A few practical steps go a long way:
- Read the revenue breakdown in Regeneron's quarterly filings rather than the headline number. The split between Eylea, Eylea HD, and Dupixent profit share tells you where the business actually stands.
- Listen to earnings calls for pipeline updates, especially genetic medicine milestones and oncology trial data.
- Compare valuation against profitable biotech peers of similar size, not against the broader market, since biotech earnings tend to be lumpier.
- Size the position appropriately. Even well-run biotechs can drop sharply on a single trial result or regulatory decision.
This article is for general information, not personalized financial advice. Your own situation, time horizon, and risk tolerance should drive any decision.
Questions People Ask About REGN
What does REGN stand for? It is simply the ticker symbol under which Regeneron Pharmaceuticals trades on the Nasdaq exchange.
Does Regeneron pay a dividend? No. The company returns capital through share buybacks and reinvests heavily in research and development.
What is Regeneron's biggest drug? Measured by global sales, Dupixent is now the company's most valuable product, though its revenue is shared with Sanofi. Eylea was historically the largest contributor to Regeneron's own reported revenue.
Is REGN a good long-term investment? That depends on whether the pipeline converts into products that replace Eylea's fading contribution and extend Dupixent's run. The company has a strong research track record and a profitable base, but the risks above are real and should be priced into any decision.
REGN represents a mature biotech with proven science, visible challenges in its legacy franchise, and a research engine that has repeatedly produced new blockbusters. Understanding both sides of that equation is the starting point for any informed view of the stock.